14 terminated. 14 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 14 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | Phase 2 | Terminated | Mayo Clinic | 3 | 2023-02-20 | 2024-09-19 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) Ruxolitinib, Anagrelide, Placebo - MPN (Myeloproliferative Neoplasms) | Phase 2 | Terminated | Incyte Corporation | 12 | 2017-11-14 | 2021-11-19 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia | Phase 2 / Phase 3 | Terminated | French Innovative Leukemia Organisation | 13 | 2017-01-03 | 2021-06-29 |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) Pacritinib, Busulfan, Questionnaires - Myeloproliferative Diseases | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2015-06-15 | 2018-10-30 |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia Momelotinib - Polycythemia Vera, Essential Thrombocythemia | Phase 2 | Terminated | Sierra Oncology LLC - a GSK company | 39 | 2014-02-19 | 2020-04-20 |
| Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis Dacogen - Chronic Myeloproliferative Disorders, Secondary Myelofibrosis | Phase 2 | Terminated | Mayo Clinic | 4 | 2008-03-01 | 2015-12-30 |
| Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) FERINJECT® (Ferric carboxymaltose), Placebo - Thrombocytosis, Iron-Deficiency Anemia | Phase 2 | Terminated | Vifor Pharma | 26 | 2006-12-01 | 2010-04-08 |
| Azacitidine in Treating Patients With Myelofibrosis azacitidine - Chronic Myeloproliferative Disorders, Secondary Myelofibrosis | Phase 2 | Terminated | Mayo Clinic | 10 | 2006-08-01 | 2011-04-21 |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease anti-thymocyte globulin, cyclophosphamide, cyclosporine - Leukemia, Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 13 | 2005-11-01 | 2017-06-14 |
| Imatinib Mesylate in Treating Patients With Myelofibrosis imatinib mesylate - Chronic Myeloproliferative Disorders | Phase 2 | Terminated | OHSU Knight Cancer Institute | 10 | 2005-08-01 | 2012-01-13 |
| Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML Total Body Irradiation, Fludarabine, Campath 1H - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Terminated | Baylor College of Medicine | 7 | 2001-12-01 | 2012-10-10 |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation anti-thymocyte globulin, busulfan, cyclophosphamide - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 1997-09-01 | 2012-12-11 | |
| Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia cyclophosphamide, cyclosporine, fludarabine phosphate - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 51 | 2013-05-01 |
Thrombocythemia, Essential (12) · Myeloproliferative Disorders (11) · Polycythemia Vera (10) · Primary Myelofibrosis (9) · Leukemia (4) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Anemia, Refractory (2) · Anemia, Refractory, with Excess of Blasts (2) · Blast Crisis (2) · Congenital Abnormalities (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Accelerated Phase (2)
Hemic and Lymphatic Diseases (14) · Blood Platelet Disorders (13) · Bone Marrow Diseases (13) · Hematologic Diseases (13) · Blood Coagulation Disorders (11) · Hemorrhagic Disorders (11) · Bone Marrow Neoplasms (10) · Hematologic Neoplasms (10) · Neoplasms (10) · Neoplasms by Site (10) · Chronic Disease (4) · Disease Attributes (4) · Leukemia, Myeloid (4) · Neoplasms by Histologic Type (4)
fludarabine phosphate (4) · Cyclophosphamide (3) · Cyclosporine (3) · ruxolitinib (3) · Antilymphocyte Serum (2) · Busulfan (2) · Methylprednisolone (2) · Radiotherapy (2) · Stem Cell Transplantation (2) · Whole-Body Irradiation (2) · anagrelide (2) · fludarabine (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Alemtuzumab (1) · Azacitidine (1)
Mayo Clinic (3) · Baylor College of Medicine (1) · Fred Hutchinson Cancer Center (1) · French Innovative Leukemia Organisation (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Sierra Oncology LLC - a GSK company (1) · Vifor Pharma (1)
United States (12) · France (2) · Australia (1) · Austria (1) · Canada (1) · Germany (1)
Ruben A. Mesa, MD (2) · Abhishek A. Mangaonkar, M.B.B.S. (1) · Albert Assad, MD (1) · Bipin N. Savani, MD (1) · Christoph Gasche, MD (1) · Colleen Delaney, MD, MSC (1) · George Carrum, MD (1) · Michael Mauro, MD (1) · Peter Lee, MD, PhD (1) · Steven C. Goldstein, MD (1) · Uday Popat, MD (1) · Uma Borate, MD (1)
P30CA015083 (2), T32CA009515 (1)